Catalyst (CPRX) | Financial Analysis & Statements
Catalyst Pharmaceuticals Inc. Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
152.6M
Gross Profit
126.5M
82.91%
Operating Income
61.8M
40.52%
Net Income
52.7M
34.53%
EPS (Diluted)
$0.41
Balance Sheet Metrics
Total Assets
1.1B
Total Liabilities
149.7M
Shareholders Equity
954.3M
Debt to Equity
0.16
Cash Flow Metrics
Operating Cash Flow
36.1M
Free Cash Flow
44.9M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Catalyst Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 589.0M | 491.7M | 398.2M | 214.2M | 140.8M |
| Cost of Goods Sold | 87.3M | 68.8M | 52.0M | 34.4M | 21.9M |
| Gross Profit | 501.7M | 422.9M | 346.2M | 179.8M | 118.9M |
| Gross Margin % | 85.2% | 86.0% | 86.9% | 83.9% | 84.5% |
| Operating Expenses | |||||
| Research & Development | 12.7M | 12.6M | 93.2M | 19.8M | 16.9M |
| Selling, General & Administrative | 193.8M | 177.7M | 133.7M | 57.1M | 49.6M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 206.5M | 190.4M | 226.9M | 76.9M | 66.6M |
| Operating Income | 257.8M | 195.1M | 86.8M | 101.8M | 52.4M |
| Operating Margin % | 43.8% | 39.7% | 21.8% | 47.5% | 37.2% |
| Non-Operating Items | |||||
| Interest Income | - | - | - | - | - |
| Interest Expense | - | - | - | - | - |
| Other Non-Operating Income | 972.0K | 5.1M | 7.7M | 2.9M | 282.0K |
| Pre-tax Income | 283.5M | 216.3M | 94.5M | 104.7M | 52.7M |
| Income Tax | 69.2M | 52.4M | 23.1M | 21.6M | 13.2M |
| Effective Tax Rate % | 24.4% | 24.2% | 24.4% | 20.7% | 25.0% |
| Net Income | 214.3M | 163.9M | 71.4M | 83.1M | 39.5M |
| Net Margin % | 36.4% | 33.3% | 17.9% | 38.8% | 28.0% |
| Key Metrics | |||||
| EBITDA | 294.7M | 227.8M | 119.7M | 103.1M | 52.6M |
| EPS (Basic) | $1.75 | $1.38 | $0.67 | $0.80 | $0.38 |
| EPS (Diluted) | $1.68 | $1.31 | $0.63 | $0.75 | $0.37 |
| Basic Shares Outstanding | 122290866 | 118457673 | 106279736 | 103374606 | 103379349 |
| Diluted Shares Outstanding | 122290866 | 118457673 | 106279736 | 103374606 | 103379349 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Catalyst Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 709.2M | 517.6M | 137.6M | 298.4M | 171.4M |
| Short-term Investments | - | - | - | 0 | 19.8M |
| Accounts Receivable | 126.5M | 65.5M | 53.5M | 10.4M | 6.6M |
| Inventory | 37.2M | 19.5M | 15.6M | 6.8M | 7.9M |
| Other Current Assets | 19.4M | 1.0M | 138.0K | 354.0K | 432.0K |
| Total Current Assets | 894.0M | 623.6M | 219.3M | 320.8M | 210.1M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 1.9M | 2.2M | 2.5M | 2.8M | 3.0M |
| Goodwill | 131.7M | 156.7M | 194.0M | 32.5M | 0 |
| Intangible Assets | 131.7M | 156.7M | 194.0M | 32.5M | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 52.8M | 46.0M | 36.5M | 18.7M | 23.7M |
| Total Non-Current Assets | 209.9M | 227.8M | 250.8M | 54.8M | 27.7M |
| Total Assets | 1.1B | 851.4M | 470.1M | 375.6M | 237.8M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 11.2M | 16.6M | 14.8M | 4.0M | 2.8M |
| Short-term Debt | 437.0K | 402.0K | 369.0K | 337.0K | 308.0K |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 840.0K | 417.0K | 465.0K | 238.0K | 243.0K |
| Total Current Liabilities | 147.2M | 120.7M | 76.1M | 57.6M | 27.1M |
| Non-Current Liabilities | |||||
| Long-term Debt | 2.4M | 2.8M | 3.2M | 3.6M | 3.9M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | 209.0K | 315.0K | 485.0K | 14.1M | - |
| Total Non-Current Liabilities | 2.6M | 3.1M | 6.2M | 17.6M | 3.9M |
| Total Liabilities | 149.7M | 123.8M | 82.2M | 75.2M | 31.0M |
| Equity | |||||
| Common Stock | 123.0K | 121.0K | 107.0K | 105.0K | 103.0K |
| Retained Earnings | 474.2M | 285.2M | 121.3M | 49.9M | -26.3M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 954.3M | 727.6M | 387.9M | 300.4M | 206.8M |
| Key Metrics | |||||
| Total Debt | 2.8M | 3.2M | 3.6M | 3.9M | 4.2M |
| Working Capital | 746.9M | 502.9M | 143.3M | 263.2M | 183.0M |
Balance Sheet Composition
Catalyst Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 214.3M | 163.9M | 71.4M | 83.1M | 39.5M |
| Depreciation & Amortization | 37.9M | 37.8M | 32.9M | 1.2M | 192.0K |
| Stock-Based Compensation | 24.8M | 22.3M | 14.2M | 7.9M | 6.1M |
| Working Capital Changes | -84.9M | -14.4M | -37.3M | -1.9M | -4.5M |
| Operating Cash Flow | 185.2M | 199.5M | 146.6M | 99.7M | 50.9M |
| Investing Activities | |||||
| Capital Expenditures | -58.0K | -556.0K | -231.0K | -29.0K | -1.0M |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | 0 | 0 | -13.5M | 0 | -10.0M |
| Investment Sales | - | 0 | 0 | 19.2M | 0 |
| Investing Cash Flow | -58.0K | -556.0K | -212.0M | 9.2M | -11.0M |
| Financing Activities | |||||
| Share Repurchases | -25.3M | -296.0K | 0 | -6.9M | -12.1M |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | - | - | - | - | - |
| Financing Cash Flow | -31.7M | 127.2M | -13.6M | -7.9M | -12.2M |
| Free Cash Flow | 208.6M | 239.3M | 61.9M | 116.0M | 59.4M |
| Net Change in Cash | 153.5M | 326.1M | -79.0M | 101.0M | 27.6M |
Cash Flow Trend
Catalyst Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
15.26
Forward P/E
8.23
Price to Book
3.29
Price to Sales
5.35
PEG Ratio
-1.79
Profitability Ratios
Profit Margin
36.39%
Operating Margin
40.53%
Return on Equity
25.49%
Return on Assets
16.48%
Financial Health
Current Ratio
6.08
Debt to Equity
0.29
Beta
0.66
Per Share Data
EPS (TTM)
$1.68
Book Value per Share
$7.79
Revenue per Share
$4.82
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| CPRX | 3.4B | 15.26 | 3.29 | 25.49% | 36.39% | 0.29 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Axsome Therapeutics | 9.5B | -50.54 | 105.31 | -252.12% | -28.69% | 247.03 |
| Praxis Precision | 9.6B | - | 9.46 | -45.83% | 0.00% | 0.01 |
| Bio-Techne | 9.1B | 117.16 | 4.55 | 3.80% | 6.41% | 20.07 |
Financial data is updated regularly. All figures are in the company's reporting currency.






